COST

971.06

-2.65%↓

PG

159.11

+1.2%↑

PM

182.72

+0.51%↑

PEP

166.96

+0.28%↑

MO

64.39

-0.05%↓

COST

971.06

-2.65%↓

PG

159.11

+1.2%↑

PM

182.72

+0.51%↑

PEP

166.96

+0.28%↑

MO

64.39

-0.05%↓

COST

971.06

-2.65%↓

PG

159.11

+1.2%↑

PM

182.72

+0.51%↑

PEP

166.96

+0.28%↑

MO

64.39

-0.05%↓

COST

971.06

-2.65%↓

PG

159.11

+1.2%↑

PM

182.72

+0.51%↑

PEP

166.96

+0.28%↑

MO

64.39

-0.05%↓

COST

971.06

-2.65%↓

PG

159.11

+1.2%↑

PM

182.72

+0.51%↑

PEP

166.96

+0.28%↑

MO

64.39

-0.05%↓

Search

Lifecore Biomedical Inc

Closed

SectorConsumer defensive

7.37 -0.14

Overview

Share price change

24h

Current

Min

7.15

Max

7.58

Key metrics

By Trading Economics

Income

-7.9M

-10M

Sales

-5.3M

31M

Profit margin

-32.116

Employees

406

Dividends

By Dow Jones

Next Earnings

13 lut 2026

Market Stats

By TradingEconomics

Market Cap

-201K

241M

Previous open

7.51

Previous close

7.37

News Sentiment

By Acuity

50%

50%

63 / 133 Ranking in Consumer defensive

Lifecore Biomedical Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 lut 2026, 23:26 UTC

Major Market Movers

Moderna Stock Slips After FDA Refuses Flu Vaccine Review

10 lut 2026, 22:31 UTC

Earnings

Correction to America Movil 4Q Profit Article

10 lut 2026, 22:22 UTC

Earnings

America Movil 4Q Profit Jumps on Lower Financial Costs

10 lut 2026, 23:51 UTC

Market Talk
Earnings

Commonwealth Bank's Margin Management Gives It a Platform -- Market Talk

10 lut 2026, 23:42 UTC

Market Talk

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

10 lut 2026, 23:40 UTC

Market Talk
Earnings

Commonwealth Bank Bear Says 1H Result Looks Strong -- Market Talk

10 lut 2026, 23:21 UTC

Market Talk

Ford Says EV Shift Was Driven by Demand Changes -- Market Talk

10 lut 2026, 23:21 UTC

Market Talk

Global Equities Roundup: Market Talk

10 lut 2026, 22:17 UTC

Market Talk

Australia's One Nation Now Commands Working Class Vote -- Market Talk

10 lut 2026, 22:15 UTC

Earnings

Humana Earnings Will Shed More Light on Medicare Prospects -- Barrons.com

10 lut 2026, 22:10 UTC

Earnings

Intact Financial 4Q Book Value Per Share Was C$107.35 >IFC.T

10 lut 2026, 22:10 UTC

Earnings

Intact Financial Raises Qtr Dividend to C$1.47 >IFC.T

10 lut 2026, 22:09 UTC

Earnings

Intact Financial 4Q Combined Ratio Was 85.9% >IFC.T

10 lut 2026, 22:09 UTC

Earnings

Intact Financial 4Q Adj EPS C$5.50 >IFC.T

10 lut 2026, 22:01 UTC

Earnings

Intact Financial 4Q EPS C$5.24 >IFC.T

10 lut 2026, 21:54 UTC

Earnings

James Hardie Industries Sees FY26 Total Adjusted EBITDA $1.232B to $1.263B >JHX

10 lut 2026, 21:53 UTC

Earnings

Robinhood Stock Tumbles as Crypto-Related Revenue Falls Short of Expectations -- Barrons.com

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries Sees FY26 Free Cash Flow at Least $200M

10 lut 2026, 21:51 UTC

Earnings

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries: Focused on the Achievement of $125 M Target >JHX

10 lut 2026, 21:51 UTC

Earnings

James Hardie Industries: Integration and Cost Synergies Ahead of Schedule >JHX

10 lut 2026, 21:51 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution Net Debt A$362 Million at Dec. 31 Vs A$1.29 Billion Year Earlier

10 lut 2026, 21:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution: Gearing 6% at Dec. 31, From 23% a Year Earlier

10 lut 2026, 21:50 UTC

Earnings

James Hardie Industries 3Q EPS 12c >JHX

10 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

10 lut 2026, 21:50 UTC

Earnings

James Hardie Industries 3Q Adj EPS 24c >JHX

10 lut 2026, 21:49 UTC

Earnings

James Hardie Industries 3Q Sales $1.24B >JHX

10 lut 2026, 21:49 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution 1H Operating Mine Cash Flow a Record A$1.73 Billion

10 lut 2026, 21:48 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution 1H Ebitda A$1.56 Billion, Up 59% On-Year

10 lut 2026, 21:47 UTC

Earnings
Acquisitions, Mergers, Takeovers

Evolution 1H Revenue A$2.79 Billion, Up 37% On-Year

Peer Comparison

Price change

Lifecore Biomedical Inc Forecast

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Sentiment

By Acuity

63 / 133 Ranking in Consumer defensive

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
help-icon Live chat